Prothena CEO Dale Schenck Dies From Pancreatic Cancer
Prothena CEO Dale Schenk, the scientist behind innovative medicines that included bapineuzumab and Tysabri, died from pancreatic cancer on Sept. 30 – less than two years after he revealed his diagnosis.
You may also be interested in...
Prothena views potential approval of Biogen’s aducanumab as a flag in the sand for next-generation amyloid-targeting therapies to race past, including the firm’s own antibody and vaccine programs.
Eli Lilly & Co. concedes that its revised primary endpoint for the ongoing Phase III clinical trial testing solanezumab in mild Alzheimer's patients goes against US FDA and European Medicines Agency (EMA) requirements, but the company is "hopeful" the change still will support regulatory approvals.
It takes weeks to recover from the biopharma industry's yearly pilgrimage to San Francisco, so as Scrip continues to sort through notes taken and business cards collected during the 34th Annual J.P. Morgan Healthcare Conference from Jan. 11 to 14, we've put together some pipeline updates from interviews that didn't make it into our initial reporting from the meeting.